PharmaVOICE - 
April 2002
Purchase Issue

In Every Issue
Talent Pool
Biotech POOL Dr. Miguel S. BARBOSA Chugai Biopharmaceuticals hires VPof [...]
By
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES etrials Inc., [...]
By
What’s New
Expanding its offerings, inChord Communications Inc., one of the largest [...]
By
PharmaTrax
Billion in revenue predicted for ADVANCED DRUG DELIVERY SYSTEMS [...]
By
For Art’s Sake
CREATIVE review I remember the first time I saw this [...]
By
Pharma Outlet
Despite a history of new product launches, strong growth, and [...]
By

Kevin Starr

What’s on your mind: Opinions
Platform Data Intelligent guidelines regarding use of physician prescribing profiles [...]
By
Raise Your Voice: Letters
Pricing: At What Cost In your March 2002 article “The [...]
By
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh [...]
By

Taren Grom, Editor

On The Cover

Beyond the Genome — Proteomics
Drug discovery in the postgenomic era will lead researchers to focus on the proteins and biological mechanisms that cause disease as a way to develop new types of treatments that are safer and more effective BY DENISE MYSHKO When the initial map of the human genome was first published in February 2001, it quickly became [...]
By

Denise Myshko

Features

Chris Snell — Enjoying the Ride
Many dream of forming their own business, one that would blos som into a highly successful company without losing sight of its vivac ity. Chris Snell — president of creative services at inChord Communications Inc., and a founding partner of Gerbig, Snell/Weisheimer & Associates, now a division of inChord — is one of those rare [...]
By

Kim Ribbink

The Nose Knows
Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a noninjection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceuticals Ltd., a U.K.based niche pharmaceuti cal company is [...]
By

Taren Grom, Editor

Planting the Seeds of a Blockbuster
Until fairly recently, top tier pharmaceutical companies obtained license rights to a product developed by a biotechnology company, thereby infusing much needed capital for furtherance of clinical research. In return, the pharmaceutical company obtained outright or major ity rights to marketing and manufacturing. In 2000, biotech companies saw their bank accounts increase exponentially as venture [...]
By
Coming Into Focus
The pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according to data from IMS Health. There are no Japanese companies in the [...]
By

Kim Ribbink

FEEDBACK